Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) Given Average Recommendation of “Buy” by Analysts
Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) has been given an average rating of “Buy” by the six brokerages that are currently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1-year price objective among analysts that have covered the stock in the last year is $13.33.
Several equities analysts recently issued reports on the stock. Zacks Investment Research lowered shares of Aeglea Bio Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday. Needham & Company LLC started coverage on shares of Aeglea Bio Therapeutics in a report on Tuesday, May 26th. They issued a “buy” rating and a $11.00 target price on the stock. BidaskClub upgraded shares of Aeglea Bio Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, June 17th. Piper Sandler started coverage on shares of Aeglea Bio Therapeutics in a report on Monday, May 4th. They set an “overweight” rating and a $12.00 price objective on the stock. Finally, HC Wainwright dropped their price objective on shares of Aeglea Bio Therapeutics from $18.00 to $17.00 and set a “buy” rating on the stock in a report on Friday, May 8th.
In other Aeglea Bio Therapeutics news, CEO Anthony G. Quinn bought 165,000 shares of the firm’s stock in a transaction dated Thursday, April 30th. The stock was bought at an average cost of $4.75 per share, with a total value of $783,750.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 13.70% of the stock is currently owned by corporate insiders.
AGLE stock traded up $0.09 during mid-day trading on Tuesday, hitting $9.25. 253,687 shares of the company were exchanged, compared to its average volume of 185,774. The business has a 50 day simple moving average of $8.78 and a 200-day simple moving average of $7.26. The company has a current ratio of 3.17, a quick ratio of 3.17 and a debt-to-equity ratio of 0.11. The stock has a market capitalization of $410.70 million, a PE ratio of -3.81 and a beta of 2.08. Aeglea Bio Therapeutics has a 1-year low of $3.50 and a 1-year high of $11.38.
Aeglea Bio Therapeutics (NASDAQ:AGLE) last announced its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.57) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.08. Equities research analysts expect that Aeglea Bio Therapeutics will post -1.71 earnings per share for the current year.
About Aeglea Bio Therapeutics
Aeglea BioTherapeutics, Inc, a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in early clinical development stage for the treatment of Arginase 1 deficiency, an autosomal recessive metabolic disease caused by a marked decrease in the activity of the native arginase 1 enzyme; and for treating Arginine dependent cancers.
Read More: What is the operating income formula?
Receive News & Ratings for Aeglea Bio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.